AstraZeneca plc  

(Public, LON:AZN)   Watch this stock  
Find more results for AZN
4,415.50
-71.00 (-1.58%)
Mar 6 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 4,408.50 - 4,528.50
52 week 3,718.50 - 5,750.00
Open 4,528.50
Vol / Avg. 2.08M/2.61M
Mkt cap 55.93B*
P/E 68.95
Div/yield 125.00/4.03*
EPS 0.64*
Shares 1.26B
Beta     -
Inst. own     -
*GBP
Apr 24, 2015
Q1 2015 AstraZeneca PLC Earnings Release - 8:00AM GMT+1 - Add to calendar
Apr 24, 2015
AstraZeneca PLC Annual Shareholders Meeting Add to calendar
Feb 5, 2015
Full Year 2014 AstraZeneca PLC Earnings Call - Webcast
Feb 5, 2015
Full Year 2014 AstraZeneca PLC Earnings Release
Jan 14, 2015
AstraZeneca PLC at JPMorgan Healthcare Conference
  

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -4.80% 4.73%
Operating margin -5.22% 8.19%
EBITD margin - 32.19%
Return on average assets -2.24% 2.16%
Return on average equity -6.43% 5.75%
Employees 51,500 -
CDP Score - 93 A

Address

2 Kingdom Street, Paddington
LONDON, W2 6BD
United Kingdom - Map
+44-20-76048000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. In January 2014, Probiodrug AG transferred its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca. In February 2014, Bristol-Myers Squibb Co completed the sale of its global diabetes business to AstraZeneca.

Officers and directors

Pascal Soriot Chief Executive Officer, Executive Director
Age: 55
Marc Dunoyer Chief Financial Officer, Executive Director
Age: 61
Ruud Dobber Executive Vice President, Europe
Caroline Hempstead Interim Executive Vice-President, Human Resources & Corporate Affairs
Paul Hudson Executive Vice President, North America
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Mark Mallon Executive Vice President, International
Briggs Morrison Executive Vice President - Global Medicines Development
Menelas Pangalos Executive Vice President - Innovative Medicines
David Smith Executive Vice President - Operations and Information Services